The inspection by the FDA has been rescheduled from the previously confirmed dates to take place within the next thirty days.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
| 10/13/2022 | $70.00 | Buy | Mizuho |
| 8/24/2022 | $107.00 | Buy | B. Riley Securities |
| 11/10/2021 | $88.00 → $90.00 | Overweight | Stephens & Co. |
| 8/3/2021 | $68.00 → $78.00 | Neutral | Goldman Sachs |
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August. "Raj has quickly become a trusted and vital colleague to me and many others at Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "His depth of knowledge about our business and industry are matched by a clear vision of what we must do to achieve success as
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Leslie Gillin to its Board of Directors, effective immediately. "We are very pleased to welcome Leslie to the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "She is extraordinarily accomplished in consumer marketing and finance, and her experience and insights will be invaluable as we continue to transform our industry by engaging directly with patients and by advancing new business and payment models." "I couldn't be
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024. Second Quarter Highlights and Outlook Second quarter worldwide revenue of $44.1 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Gross profit for the second quarter was $28.9 million, or 65.6% of revenue, compared to $30.3 million, or 62.3% of revenue in the year-ago period. Second quarter loss from operations was $9.3 million compared to a loss of $13.7 milli
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Canada) or (646) 307-1963 (International) and use conference ID number 7160745. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishme
- SEC Filing
Citigroup analyst Joanne Wuensch maintains Establishment Labs Hldgs (NASDAQ:ESTA) with a Neutral and lowers the price target from $60 to $50.
Mizuho analyst Anthony Petrone maintains Establishment Labs Hldgs (NASDAQ:ESTA) with a Buy and raises the price target from $65 to $70.
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021. In the preliminary three-year analysis of key complications, there were no reports of capsular contracture (Baker Grade III/IV) and no ruptures (suspected or confirmed). There were also no report
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report. "It is fitting that as we publish our 2024 PMS report, we begin broadly shipping across the United States," said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. "Dozens of plastic surgeons will perform their first Motiva surgery in the coming days, and they are actively talking about the advantages of Motiva Implants on social media. Many women are responding, accepting only Motiva Implants for their surgery. Not
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00
JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00
Citigroup initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $79.00